Highlights of This Issue

THERAPEUTIC DISCOVERY

First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Downregulation in Human Neoplasm: Implication for Resistance to Therapeutics in Prostate Cancer
Leyre Brizuela, Isabelle Ader, Catherine Mazeron, Magalie Bocquet, Bernard Malavaud, and Olivier Cuvillier

Induction of the Transcriptional Repressor ZBTB4 in Prostate Cancer Cells by Drug-Induced Targeting of MicroRNA-17-92/106b-25 Clusters
KyoungHyun Kim, Gayathri Chadalapaka, Satya S. Pathi, Un-Ho Jin, Ju-Seog Lee, Yun-Yong Park, Sung-Gook Cho, Sudhakar Chintharlapalli, and Stephen Safe

A Role for Homologous Recombination and Abnormal Cell-Cycle Progression in Radioresistance of Glioma-Initiating Cells

Oxidative Stress Induced by Curcumin Promotes the Death of Cutaneous T-cell Lymphoma (HuT-78) by Disrupting the Function of Several Molecular Targets
Mohammad Aslam Khan, Satindra Gahlot, and Sekhar Majumdar

Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the βGBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo
Livio Mallucci, Dong-yun Shi, Derek Davies, Peter Jordan, Alastair Nicol, Lavinia Lotti, Renato Mariani-Costantini, Fabio Verginelli, Valerie Wells, and Daniel Zicha

PRECLINICAL DEVELOPMENT

Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts
Muralidharan Anbalagan, Alan Alai, Ryan K. Jones, Carolyn G. Marsden, Mei Sheng, Latonya Carrier, Yahao Bu, David Hangauer, and Brian G. Rowan
1948  Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models
Caroline C. Clark, Jeffrey N. Weitzel, and Timothy R. O’Connor

1959  TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells
Daniel P. Fitzgerald, David L. Emerson, Yongzhen Qian, Talha Anwar, David J. Lievehr, Seth M. Steinberg, Sandra Silberman, Diane Palmieri, and Patricia S. Steeg

1968  Evidence for the Ubiquitin Protease UBP-43 as an Antineoplastic Target
Yongli Guo, Fadzai Chinyengetere, Andrey V. Dolinko, Alexandra Lopez-Aguirau, Yun Lu, Fabrizio Galimberti, Tian Ma, Qing Feng, David Sekula, Sarah J. Freemantle, Angelina S. Andrew, Vincent Memoli, and Ethan Dmitrovsky

1978  Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

1988  YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels
Bhavna Kumar, Arti Yadav, James C. Lang, Michael J. Cipolla, Alessandra C. Schmitt, Nicole Arradaza, Theodoros N. Teknos, and Pawan Kumar

1999  The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models
Masamichi Mizuma, Zeshaan A. Rasheed, Shinichi Yabuuchi, Noriyuki Omura, Nathaniel R. Campbell, Roeland F. de Wilde, Elizabeth De Oliveira, Qing Zhang, Oscar Puig, William Matsui, Manuel Hidalgo, Anirban Maitra, and N.V. Rajeshkumar

2000  Fibroblast Growth Factor Receptor 2 IIIc as a Therapeutic Target for Colorectal Cancer Cells
Yoko Matsuda, Masahito Hagoi, Tomoko Seya, and Toshiyuki Ishiwata

2010  Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion

2012  MOLECULAR MEDICINE IN PRACTICE

2013  Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials
Rodrigo Dienstmann, Danila Serpico, Jordi Rodon, Cristina Saura, Teresa Macarulla, Elena Elez, Maria Alinsa, Jaime Capdevila, Jose Perez-Garcia, Gessami Sanchez-Olle, Claudia Aura, Luimila Prudkin, Stefania Landolfi, Javier Hernandez-Losa, Ana Vivancos, and Josep Tabernero

2014  Correction: Proanthocyanidins Inhibit In Vitro and In Vivo Growth of Human Non–Small Cell Lung Cancer Cells by Inhibiting the Prostaglandin E2 and Prostaglandin E2 Receptors

2015  Correction: Proanthocyanidins Inhibit In Vitro and In Vivo Growth of Human Non–Small Cell Lung Cancer Cells by Inhibiting the Prostaglandin E2 and Prostaglandin E2 Receptors

2016  Correction: Proanthocyanidins Inhibit In Vitro and In Vivo Growth of Human Non–Small Cell Lung Cancer Cells by Inhibiting the Prostaglandin E2 and Prostaglandin E2 Receptors

2017  Correction: Proanthocyanidins Inhibit In Vitro and In Vivo Growth of Human Non–Small Cell Lung Cancer Cells by Inhibiting the Prostaglandin E2 and Prostaglandin E2 Receptors
Immunohistochemical staining of colorectal cancer tissues using anti-FGFR2IIIc antibody. The tumor cell cytoplasm and cell membrane of adenocarcinoma showed strong immunoreactivity for FGFR2IIIc, which is a splicing isoform of FGFR2. FGFR2IIIc immunoreactivity was expressed in 27% of colorectal cancer cases, and this expression correlated with distant metastasis and poor prognosis. FGFR2IIIc-transfected colorectal cancer cells formed larger tumors in subcutaneous tissues and the cecum of immunodeficient mice. Fully human anti-FGFR2IIIc monoclonal antibody inhibited the growth and migration of colorectal cancer cells. For details, see the article by Matsuda and colleagues on page 2010.